On demand videos

Panel discussion: The panel discuss how they have adapted their working practices during the COVID-19 pandemic, such as virtual meetings with patients, and highlight the advantages and disadvantages of these new ways of working. They also consider the impact of these changes on future patient care.

Source:  Focus webcast 3 (2 September 2020)

Presentation: Prof. Richard Chin talks about the challenges his team faced during the COVID-19 pandemic and solutions they developed to facilitate remote consultations and monitoring. This includes vCreate, a cloud-based bidirectional video interface securing asynchronous video transfer, classification and storage for neurological care.

Presentation: Prof. Sameer Zuberi describes the updated International League Against Epilepsy definition of LGS, including mandatory criteria such as seizure type and EEG features. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)
 

Presentation: Prof. Ulrich Brandl describes the presentation of LGS from a paediatric neurologist's perspective and provides an overview of the evolving clinical condition of LGS. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Presentation and case study: Prof. Selim Benbadis discusses the presentation of LGS and its challenges from an adult neurologist's perspective, and highlights important considerations using a clinical case of a 26-year-old male patient. Followed by a Q&A discussion. 

Source: Focus webcast 5 (10 December 2020)

Presentation: Prof. Bernhard Steinhoff summarises the current treatment guidelines for LGS and DS and discusses the journey of patients with LGS and DS from childhood to adulthood, including age-related treatment considerations and challenges for caregivers and neurologists.

Presentation: Prof. Angela Kaindl presents an overview of her centre's experience with GW CBD in 28 paediatric patients with LGS. Dosage and titration of GW CBD and short-term observations, including adverse effects, both positive and negative are covered. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Selim Benbadis presents a clinical case of a 25-year-old female patient with LGS, describing the diagnosis of LGS and the introduction and slow titration of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Angela Kaindl presents a clinical case of a 13-year-old female patient with LGS (ANKRD11 mutation) who was initiated on 2 mg/kg/day GW CBD, which was titrated up weekly to a dose of 15 mg/kg/day. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Selim Benbadis describes a clinical case of a 15-year-old female patient with LGS who had previously been taking a non-regulatory approved cannabis-based product prior to receiving GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case demonstrating the reintroduction of clobazam prior to initiation of GW CBD in a 12-year-old male patient with LGS. Clobazam had initially been withdrawn due to minimal efficacy and poor tolerability. Followed by a Q&A discussion.

Source: Focus webcast 3 (2 September 2020)

Case study: Prof. Angela Kaindl presents two clinical case studies, one of a 6-year-old female patient with LGS and one of a 9-year-old male patient with LGS, demonstrating how patients may respond differently following initiation of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Ulrich Brandl presents a clinical case of an 8-year-old male patient with LGS who exhibited behavioural problems prior to initiation and titration of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Selim Benbadis presents a clinical case describing the initiation of GW CBD in a 26-year-old male patient with LGS secondary to Down's syndrome. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Angela Kaindl presents a clinical case describing the introduction and dose management of GW CBD in a 9-year-old male patient with LGS. Followed by a Q&A discussion with Prof. Selim Benbadis who had presented a case study on an adult male patient with LGS.

Source: Focus webcast 3 (2 September 2020)

Case study: Prof. Selim Benbadis presents a clinical case of a 19-year-old male patient with LGS, describing the diagnosis of LGS and the introduction of GW CBD. Followed by a Q&A discussion with Prof. Angela Kaindl who had presented a case study on a paediatric male patient with LGS.

Source: Focus webcast 3 (2 September 2020)

Case study: Prof. Elizabeth Thiele presents a patient profile, describing the introduction of GW CBD in a 22-year-old female patient with DS who was refractory to multiple ASMs. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case describing the initiation of GW CBD in a 5-year-old male patient with DS. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Bernhard Steinhoff presents a clinical case describing the partial initial efficacy following initiation of GW CBD in a 22-year-old male patient with DS who had been refractory to many other ASMs. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 19-year-old male patient with LGS, and describes the management of adverse events, including lethargy and decreased appetite. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 10-year-old male patient with DS who experienced diarrhoea due to a sesame oil allergy. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 25-year-old female patient with LGS in the setting of tuberous sclerosis complex who experienced behavioural problems due to a suspected DDI. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Case study: Prof. Andreas Schulze-Bonhage presents a clinical case of a 30-year-old male patient with LGS. He describes the management of adverse events, including nausea, vomiting and elevated transaminase levels. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Andreas Schulze-Bonhage presents a clinical case of a 31-year-old male patient with LGS with idiosyncratic intolerability due to a specific genetic defect in CBD metabolism. The patient experienced difficulties in concentration and double vision when taking GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Sameer Zuberi presents a clinical case of a 15-year-old female patient with DS who experienced diarrhoea following introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Bernhard Steinhoff presents a clinical case of a 28-year-old female patient with LGS who experienced increased sedation following introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Bernhard Steinhoff presents a clinical case of a 34-year-old male patient with LGS who experienced somnolence after introduction of GW CBD and clobazam. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Presentation and case study: Prof. Sameer Zuberi presents an overview of polytherapy in LGS and DS. He also covers potential DDIs with GW CBD and common ASMs. He also provides an overview of the additional monitoring required with GW CBD, which he illustrates using a clinical case of a 4-year-old female patient with LGS. Followed by a Q&A discussion.

Source: Focus webcast 3 (2 September 2020)

Presentation: Prof. Ulrich Brandl describes the implications of polytherapy in LGS for GW CBD, including a summary of DDIs, clinical problems and recommendations for the introduction of GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Case study: Prof. Bernhard Steinhoff describes the follow up required, in case of possible DDIs, in a clinical case of a 27-year-old male patient with LGS on a baseline combination of high-dose valproate, lamotrigine, and brivaracetam upon initiation of low dose clobazam and GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 5 (10 December 2020)

Case study: Prof. Bernhard Steinhoff presents his experience of managing a 27-year-old male patient with DS who experienced drug- and diet-resistant diarrhoea when taking GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Presentation: Prof. Ulrich Brandl discusses the key considerations for introducing GW CBD in patients who have previously been taking non-regulatory approved cannabis-based products. Followed by a Q&A discussion.

Source: Focus webcast 1 (4 June 2020)

Case study: Prof. Selim Benbadis presents a clinical case of a 42-year-old male patient with LGS who initiated GW CBD after weaning off a non-regulatory approved cannabis-based product from a ‘dispensary’ at an unclear dose (< 10 mg daily). Followed by a Q&A discussion.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Selim Benbadis describes a clinical case of a 28-year-old patient who initiated GW CBD following discontinuation of an unknown dose of non-regulatory approved cannabis-based product from a ‘dispensary’. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Selim Benbadis discusses how GW CBD might be introduced in a patient who is currently receiving non-regulatory approved cannabis-based products through an illustrative clinical case study of a 7-year-old female patient.

Panel discussion: The panel address three questions from the audience covering which seizures respond best to GW CBD, the optimal dose of GW CBD, and whether there is any benefit to combining specific drugs with GW CBD.

Source: Focus webcast 2 (2 July 2020)

Case study: Prof. Elizabeth Thiele presents a clinical case of a 16-year-old female patient with LGS and describes the process of determining the optimal dose of GW CBD by reviewing the dosage and titration of clobazam and GW CBD. Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Case study: Prof. Bernhard Steinhoff presents a clinical case describing the initiation of low-dose clobazam and titration of GW CBD in a 32-year-old male patient with LGS . Followed by a Q&A discussion.

Source: Focus webcast 4 (23 September 2020)

Panel discussion: The panel discuss the placement of GW CBD in the treatment algorithms for LGS and DS, and the possibilities of it being used as an early intervention. The challenges surrounding syndromic diagnosis is highlighted as a barrier to early intervention.

Source: Focus webcast 4 (23 September 2020)

Presentation: Nick Jones, PhD, discusses developments in cannabinoid medical research, regulatory versus non-regulatory approved cannabis-based products, and the molecular pharmacology and proposed mechanism of action of CBD in epilepsy.

During this webcast, the expert faculty discussed:

• GW CBD patient profile 
• Starting and maintaining patients on GW CBD
• Managing adverse events associated with GW CBD 
• GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
   

During this webcast, the expert faculty discussed:

• GW CBD patient profile 
• Starting and maintaining patients on GW CBD
• Managing adverse events associated with GW CBD 
• GW CBD in patients who have tried or who are currently receiving unlicensed cannabis-based products
   

During this webcast, the expert faculty discussed: 

• Identifying patients that might benefit from GW CBD
• Reintroducing clobazam in patients who have previously tried and discontinued clobazam
• Polytherapy and monitoring requirements
• Transition from paediatric to adolescent/adult care
• Epilepsy care and implications for GW CBD treatment in the times of COVID-19
   

During this webcast, the expert faculty discussed:

• When to consider GW CBD
• The importance of diagnosis: LGS in adult patients
• Managing adverse events associated with GW CBD
• Determining the optimal dose of GW CBD 
• Initiating GW CBD in patients who have tried or who are currently receiving non-regulatory approved cannabis-based products
• Early versus late intervention with GW CBD
   

This webcast focused on the diagnosis and management of patients with LGS. The expert faculty discussed:

• The importance of diagnosis in patients with LGS, including syndromic diagnoses
• Cognitive and behavioural problems in patients with LGS receiving GW CBD
• How to best manage polytherapy in patients with LGS receiving GW CBD
• The evolution of LGS and implications for treatment, as well as diagnosis in adult patients